BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Principi M, Iannone A, Losurdo G, Mangia M, Shahini E, Albano F, Rizzi SF, La Fortezza RF, Lovero R, Contaldo A, Barone M, Leandro G, Ierardi E, Di Leo A. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018;24:1589-1596. [PMID: 29688336 DOI: 10.1093/ibd/izy051] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Tsai YW, Fu SH, Dong JL, Chien MW, Liu YW, Hsu CY, Sytwu HK. Adipokine-Modulated Immunological Homeostasis Shapes the Pathophysiology of Inflammatory Bowel Disease. Int J Mol Sci 2020;21:E9564. [PMID: 33334069 DOI: 10.3390/ijms21249564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
3 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. Pathogens. 2020;9. [PMID: 33113974 DOI: 10.3390/pathogens9110870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yahya MA, Alshammari GM, Osman MA, Al-harbi LN, Yagoub AEA, Alsedairy SA. Isoliquiritigenin attenuates high-fat diet-induced intestinal damage by suppressing inflammation and oxidative stress and through activating Nrf2. Journal of Functional Foods 2022;92:105058. [DOI: 10.1016/j.jff.2022.105058] [Reference Citation Analysis]
5 Ye J, Haskey N, Dadlani H, Zubaidi H, Barnett JA, Ghosh S, Gibson DL. Deletion of mucin 2 induces colitis with concomitant metabolic abnormalities in mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G791-803. [PMID: 33728986 DOI: 10.1152/ajpgi.00277.2020] [Reference Citation Analysis]
6 Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. World J Gastroenterol 2020; 26(47): 7528-7537 [PMID: 33384552 DOI: 10.3748/wjg.v26.i47.7528] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Cheng C, Hua J, Tan J, Qian W, Zhang L, Hou X. Identification of differentially expressed genes, associated functional terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by bioinformatics analysis. Exp Ther Med 2019;18:278-88. [PMID: 31258663 DOI: 10.3892/etm.2019.7541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
8 Likhitsup A, Dundulis J, Ansari S, El-Halawany H, Michelson R, Hutton C, Kennedy K, Helzberg JH, Chhabra R. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019;32:283-286. [PMID: 31040626 DOI: 10.20524/aog.2019.0371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 McHenry S, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, Salter A, Browning JD, Flores AG, Davidson NO, Fowler KJ, Ciorba MA, Deepak P. Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clin Gastroenterol Hepatol 2019;17:2816-8. [PMID: 30876963 DOI: 10.1016/j.cgh.2019.02.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhães J, Moreira MJ, Marinho C, Cotter J. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. Eur J Gastroenterol Hepatol 2019;31:998-1003. [PMID: 30839437 DOI: 10.1097/MEG.0000000000001319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
12 Della Torre S. Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling. Front Endocrinol (Lausanne) 2020;11:572490. [PMID: 33071979 DOI: 10.3389/fendo.2020.572490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
13 Seo KI, Kang SB. [Hepatobiliary Manifestation of Inflammatory Bowel Disease]. Korean J Gastroenterol 2019;73:248-59. [PMID: 31132831 DOI: 10.4166/kjg.2019.73.5.248] [Reference Citation Analysis]
14 Szilagyi A. Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms. Clin J Gastroenterol 2020;13:139-52. [PMID: 31452062 DOI: 10.1007/s12328-019-01037-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Reference Citation Analysis]
16 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. Diagnostics (Basel). 2020;10. [PMID: 33276638 DOI: 10.3390/diagnostics10121037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 2019;7:91. [PMID: 31196177 DOI: 10.1186/s40168-019-0704-8] [Cited by in Crossref: 216] [Cited by in F6Publishing: 199] [Article Influence: 72.0] [Reference Citation Analysis]
18 Kwon J, Lee C, Heo S, Kim B, Hyun CK. DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. Sci Rep. 2021;11:5283. [PMID: 33674694 DOI: 10.1038/s41598-021-84761-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Likhitsup A, Dundulis J, Ansari S, Patibandla S, Hutton C, Kennedy K, Helzberg JH, Chhabra R. High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. Ann Gastroenterol. 2019;32:463-468. [PMID: 31474792 DOI: 10.20524/aog.2019.0405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Cronin O, Barton W, Moran C, Sheehan D, Whiston R, Nugent H, McCarthy Y, Molloy CB, O'Sullivan O, Cotter PD, Molloy MG, Shanahan F. Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: a randomized controlled cross-over trial. BMC Gastroenterol 2019;19:29. [PMID: 30755154 DOI: 10.1186/s12876-019-0952-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
21 Perez-Carreras M, Casis-Herce B, Rivera R, Fernandez I, Martinez-Montiel P, Villena V. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. World J Gastroenterol 2021; 27(41): 7113-7124 [PMID: 34887631 DOI: 10.3748/wjg.v27.i41.7113] [Reference Citation Analysis]
22 Adams LC, Lübbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. PLoS One 2018;13:e0206450. [PMID: 30427909 DOI: 10.1371/journal.pone.0206450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
23 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
24 Sato T, Tsuchiya A, Owaki T, Kumagai M, Motegi S, Iwasawa T, Nojiri S, Ogawa M, Takeuchi S, Watanabe Y, Kawata Y, Kamimura H, Terai S. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;566:36-44. [PMID: 34116355 DOI: 10.1016/j.bbrc.2021.05.097] [Reference Citation Analysis]
25 Larsen IS, Jensen BAH, Bonazzi E, Choi BSY, Kristensen NN, Schmidt EGW, Süenderhauf A, Morin L, Olsen PB, Hansen LBS, Schröder T, Sina C, Chassaing B, Marette A. Fungal lysozyme leverages the gut microbiota to curb DSS-induced colitis. Gut Microbes 2021;13:1988836. [PMID: 34693864 DOI: 10.1080/19490976.2021.1988836] [Reference Citation Analysis]
26 Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Zou ZY, Shen B, Fan JG. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25:1764-1772. [PMID: 30918952 DOI: 10.1093/ibd/izz043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
28 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]